Jan Voss

910 total citations
33 papers, 605 citations indexed

About

Jan Voss is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Jan Voss has authored 33 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Jan Voss's work include Receptor Mechanisms and Signaling (14 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Chemical Synthesis and Analysis (4 papers). Jan Voss is often cited by papers focused on Receptor Mechanisms and Signaling (14 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Chemical Synthesis and Analysis (4 papers). Jan Voss collaborates with scholars based in Germany, Sweden and Japan. Jan Voss's co-authors include Stephan M. Feller, Christian Kardinal, Guido Posern, Jie Zheng, Christa E. Müller, Beatrice S. Knudsen, Knut Adermann, Stefan Kehraus, Gabriele M. König and Asuka Inoue and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Jan Voss

32 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Voss Germany 14 373 83 68 58 55 33 605
Lihua Yu China 13 489 1.3× 128 1.5× 49 0.7× 34 0.6× 10 0.2× 47 890
Michael Churchill United States 15 462 1.2× 39 0.5× 110 1.6× 26 0.4× 15 0.3× 21 783
Katherine P. Henrikson United States 12 261 0.7× 118 1.4× 51 0.8× 115 2.0× 22 0.4× 22 640
Roger Abseher Germany 14 532 1.4× 24 0.3× 90 1.3× 69 1.2× 29 0.5× 16 822
John Kirkpatrick United Kingdom 21 918 2.5× 89 1.1× 195 2.9× 170 2.9× 56 1.0× 45 1.4k
B. Sheard United Kingdom 11 410 1.1× 42 0.5× 75 1.1× 102 1.8× 32 0.6× 12 705
Nathan S. Astrof United States 11 352 0.9× 31 0.4× 40 0.6× 75 1.3× 154 2.8× 14 791
Dorothea Kominos United States 10 799 2.1× 18 0.2× 154 2.3× 68 1.2× 51 0.9× 15 1.0k
Sengodagounder Arumugam United States 13 745 2.0× 40 0.5× 173 2.5× 47 0.8× 13 0.2× 20 1.0k
Calvin Shaller United States 14 521 1.4× 46 0.6× 368 5.4× 35 0.6× 26 0.5× 26 1.2k

Countries citing papers authored by Jan Voss

Since Specialization
Citations

This map shows the geographic impact of Jan Voss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Voss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Voss more than expected).

Fields of papers citing papers by Jan Voss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Voss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Voss. The network helps show where Jan Voss may publish in the future.

Co-authorship network of co-authors of Jan Voss

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Voss. A scholar is included among the top collaborators of Jan Voss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Voss. Jan Voss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grätz, Lukas, Ainoleena Turku, Paweł Kozielewicz, et al.. (2025). SAG1.3-derived Frizzled-targeting small-molecule compounds. Journal of Biological Chemistry. 301(11). 110751–110751.
2.
Voss, Jan, Zsombor Kőszegi, Yuting Yan, et al.. (2025). WNT-induced association of Frizzled and LRP6 is not sufficient for the initiation of WNT/β-catenin signaling. Nature Communications. 16(1). 4848–4848. 2 indexed citations
3.
Grätz, Lukas, Jan Voss, Β. W. Low, et al.. (2024). A Putative Frizzled 7-Targeting Compound Acts as a Firefly Luciferase Inhibitor. Journal of Medicinal Chemistry. 67(24). 22332–22341. 2 indexed citations
4.
Schulte, Gunnar, et al.. (2024). Frizzleds act as dynamic pharmacological entities. Trends in Pharmacological Sciences. 45(5). 419–429. 8 indexed citations
5.
Grätz, Lukas, et al.. (2024). Structural basis of frizzled 7 activation and allosteric regulation. Nature Communications. 15(1). 7422–7422. 8 indexed citations
6.
Voss, Jan, et al.. (2023). Crystal structure of adenosine A2A receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction. Communications Chemistry. 6(1). 106–106. 14 indexed citations
7.
Voss, Jan. (2023). Recommended Tool Compounds: Application of YM-254890 and FR900359 to Interrogate Gαq/11-Mediated Signaling Pathways. ACS Pharmacology & Translational Science. 6(12). 1790–1800. 3 indexed citations
8.
Voss, Jan, et al.. (2022). Irreversible Antagonists for the Adenosine A2B Receptor. Molecules. 27(12). 3792–3792. 8 indexed citations
9.
Klapschinski, Tim A., et al.. (2022). Single Stabilizing Point Mutation Enables High‐Resolution Co‐Crystal Structures of the Adenosine A2A Receptor with Preladenant Conjugates. Angewandte Chemie International Edition. 61(22). e202115545–e202115545. 13 indexed citations
10.
Voss, Jan, et al.. (2022). Agonist-Dependent Coupling of the Promiscuous Adenosine A2B Receptor to Gα Protein Subunits. ACS Pharmacology & Translational Science. 5(5). 373–386. 9 indexed citations
11.
Voss, Jan, Muhammad Rafehi, Ramón Guixà-González, et al.. (2021). Unraveling binding mechanism and kinetics of macrocyclic Gαq protein inhibitors. Pharmacological Research. 173. 105880–105880. 12 indexed citations
12.
Richarz, René, Stefan Kehraus, Jan Voss, et al.. (2021). Thioesterase-mediated side chain transesterification generates potent Gq signaling inhibitor FR900359. Nature Communications. 12(1). 144–144. 39 indexed citations
13.
Voss, Jan, Nicole Merten, Nina Heycke, et al.. (2021). An experimental strategy to probe Gq contribution to signal transduction in living cells. Journal of Biological Chemistry. 296. 100472–100472. 21 indexed citations
14.
Schneider, Marion, Stefan Kehraus, Jan Voss, et al.. (2020). Sensitive LC-MS/MS Method for the Quantification of Macrocyclic Gαq Protein Inhibitors in Biological Samples. Frontiers in Chemistry. 8. 833–833. 4 indexed citations
15.
Namasivayam, Vigneshwaran, Muhammad Rafehi, Jan Voss, et al.. (2019). Cell‐permeable high‐affinity tracers for Gq proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitors. British Journal of Pharmacology. 177(8). 1898–1916. 20 indexed citations
16.
Marziniak, Martin, Jan Voss, & Stefan Evers. (2007). Hypnic Headache Successfully Treated With Botulinum Toxin Type A. Cephalalgia. 27(9). 1082–1084. 19 indexed citations
17.
Feller, Stephan M., Gabriele Tuchscherer, & Jan Voss. (2003). High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia. Leukemia & lymphoma. 44(3). 411–427. 18 indexed citations
18.
Luber, Birgit, Sonja Candidus, Gabriele Handschuh, et al.. (2000). Tumor-Derived Mutated E-Cadherin Influencesβ-Catenin Localization and Increases Susceptibility to Actin Cytoskeletal Changes Induced by Pervanadate. Cell adhesion and communications/Cell adhesion and communication/Cell adhesion & communication. 7(5). 391–408. 31 indexed citations
19.
Voss, Jan, Guido Posern, Leanne M. Wiedemann, et al.. (2000). The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene. 19(13). 1684–1690. 61 indexed citations
20.
Posern, Guido, Jie Zheng, Christian Kardinal, et al.. (1998). Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G. Oncogene. 16(15). 1903–1912. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lihua Yu Breakdown of academic impact, for papers by Michael Churchill Breakdown of academic impact, for papers by Katherine P. Henrikson Breakdown of academic impact, for papers by Roger Abseher Breakdown of academic impact, for papers by John Kirkpatrick Breakdown of academic impact, for papers by B. Sheard Breakdown of academic impact, for papers by Nathan S. Astrof Breakdown of academic impact, for papers by Dorothea Kominos Breakdown of academic impact, for papers by Sengodagounder Arumugam Breakdown of academic impact, for papers by Calvin Shaller
Rankless by CCL
2026